Proteomics and pharmacogenomics research are two key technologies leading the change from traditional symptoms-based medicine to genetic-based personalized medicine.
By combining Iberica’s proteomics capabilities with Moritex’s pharmacogenomics capabilities (i.e., gene expression profiling services),
Sponsor’s now have access to a compelling solution for performing proteomic and polymorphic analyses. In addition to this “partnership in excellence”, Moritex also provides Iberica’s Sponsors with high-quality blood sample analyses services for clinical studies.